These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 7578667)
1. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia. Levinson I; Levine S Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667 [No Abstract] [Full Text] [Related]
2. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations. Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328 [TBL] [Abstract][Full Text] [Related]
3. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. Kopala LC; Fredrikson D; Good KP; Honer WG Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777 [No Abstract] [Full Text] [Related]
4. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Reschke RW Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080 [TBL] [Abstract][Full Text] [Related]
5. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses]. Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M Encephale; 1995; 21(6):417-24. PubMed ID: 8674466 [TBL] [Abstract][Full Text] [Related]
6. [Cognition and driving in schizophrenic patients under treatment with risperidone vs. haloperidol]. Dittert S; Soyka M; Winter C; Möller HJ Fortschr Neurol Psychiatr; 1999 Nov; Suppl 2():S70-3. PubMed ID: 10598340 [No Abstract] [Full Text] [Related]
7. Depressive symptoms and schizophrenia a psychopharmacological approach. Mauri MC; Bravin S; Fabiano L; Vanni S; Boscati L; Invernizzi G Encephale; 1995; 21(5):555-8. PubMed ID: 8529564 [TBL] [Abstract][Full Text] [Related]
8. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. Chouinard G; Safadi G; Beauclair L J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017 [TBL] [Abstract][Full Text] [Related]
9. Schizophrenia and severe tardive dyskinesia responsive to risperidone. Kopala LC; Honer WG J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794 [No Abstract] [Full Text] [Related]
10. [Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation]. Vanelle JM; Amorim P; Piketti ML; Bourdel MC; Poirier-Littré MF Encephale; 1996 Oct; 22 Spec No 3():82-4. PubMed ID: 8954284 [No Abstract] [Full Text] [Related]
11. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects. Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612 [TBL] [Abstract][Full Text] [Related]
12. Amoxapine as an antipsychotic: comparative study versus haloperidol. Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123 [TBL] [Abstract][Full Text] [Related]
13. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987 [TBL] [Abstract][Full Text] [Related]